Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| S2010 | SWOG | A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen) | Cancer Prevention and Control CIRB | Available to Open | |
| S2011 | SWOG | Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2012 | SWOG | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2013 | SWOG | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Cancer Prevention and Control CIRB | Available to Open | |
| S2015 | SWOG | Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2101 | SWOG | Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2104 | SWOG | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2107 | SWOG | Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2108CD | SWOG | A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy | Cancer Prevention and Control CIRB | Available to Open | |
| S2114 | SWOG | A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open |